Elucidation of the mechanism of cancer-related thrombosis in ovarian clear cell carcinoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09443
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: The University of Tokyo
• Principal Investigator: KASHIYAMA TOMOKO 東京大学, 医学部附属病院, 届出研究員 (70755719)
• Co-Investigator(Kenkyū-buntansha): 田口 歩 東京大学, 医学部附属病院, 届出研究員 (60756782) ; 谷川 道洋 東京大学, 医学部附属病院, 届出研究員 (70706944)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: がん関連血栓症 / 卵巣癌 / 婦人科悪性腫瘍 / 血小板凝集塊 / 血小板活性化 / 血栓治療

Outline of Final Research Achievements

Ovarian cancer is often in an advanced stage at the time of diagnosis. In recent years, treatment with PARP inhibitors and other drugs has been performed in addition to existing anticancer drugs, but it is still a disease with poor prognosis because it often shows resistance to treatment. In addition, ovarian cancer is often complicated with thrombosis, and the presence of thrombosis has a significant impact on the course of treatment, so diagnosis and treatment of thrombosis in ovarian cancer cases is very important. In this study, we analyzed the prognosis of ovarian clear cell carcinoma cases with and without thrombosis complications at our hospital and found that thrombosis complications are an independent poor prognostic factor. Furthermore, we found significant platelet activation in ovarian malignant tumors, a decrease in platelet activity due to ovarian tumor resection, and a significant increase in platelet activity around the onset of thrombosis.

Free Research Field

医学

Academic Significance and Societal Importance of the Research Achievements

卵巣癌患者における血栓症の合併は、癌治療を困難にする要素の一つであるため、適切な卵巣癌治療と血栓治療の両立は重要な課題である。今回われわれが明らかにした卵巣癌患者における血小板凝集塊測定の結果から、悪性腫瘍自体による血小板活性化の背景が示され、現行の血栓における治療としての腫瘍切除の重要性がさらに示された。今後組織型特異的な血小板活性化のメカニズムを探ることで新たな血栓治療標的の確立を目指す。